monoclon
antibodi
mab
becom
integr
part
modern
treatment
concept
cancer
inflamm
immunolog
disord
infecti
diseas
fulli
human
mab
carri
xenogen
compon
display
prefer
pharmacokinet
profil
emerg
fastestgrow
group
therapeut
antibodi
enter
clinic
sinc
first
report
product
mous
mab
employ
b
cell
hybridoma
fusion
sever
power
technolog
gener
entir
human
antibodi
includ
noncombinatori
methodolog
effici
immort
human
b
gener
stabl
human
expressionclon
physiolog
variabl
v
gene
pair
bloodderiv
human
b
cell
infect
vast
major
clinicallyinvestig
fulli
human
mab
howev
produc
either
immun
transgen
mice
equip
human
antibodi
gene
prepar
human
antibodi
phage
display
librari
latter
approach
random
pair
variabl
gene
heavi
light
antibodi
chain
vh
vl
respect
clone
combinatori
librari
involv
bacteriophag
present
select
antibodi
sinc
initi
descript
antibodi
phage
technolog
evolv
success
vitro
select
platform
human
antibodi
robust
inexpens
offer
great
potenti
first
fulli
human
phage
displayderiv
mab
recent
approv
fda
treatment
rheumat
chronic
inflammatori
bowel
diseas
adalimumab
system
lupu
erythematosu
belimumab
inhal
anthrax
infect
raxibacumab
phage
display
libraryselect
mab
current
advanc
stage
clinic
develop
may
reach
market
approv
within
next
year
past
year
plethora
phagederiv
antibodi
librari
construct
differ
design
origin
divers
method
gener
nevertheless
depend
gene
sourc
employ
antibodi
librari
group
immun
semi
synthet
librari
librari
amplifi
natur
rearrang
v
gene
primari
bcell
repertoir
healthi
wherea
immun
librari
creat
v
gene
infect
immun
donor
wide
rang
diseaserel
target
design
synthet
librari
involv
comput
approach
gene
partial
complet
segment
natur
nowaday
almost
exist
commerci
librari
base
nonimmun
repertoir
high
complex
select
highaffin
binder
expect
directli
correl
size
function
repertoir
theoret
allow
select
mab
virtual
unlimit
number
target
antigen
latest
stateofart
librari
reach
complex
clone
thu
may
even
exceed
size
individu
human
b
cell
although
librari
highli
success
recov
targetspecif
high
affin
antibodi
wide
rang
differ
antigen
usual
contain
specif
develop
cours
humor
immun
respons
vivo
nonetheless
conceiv
antibodi
deriv
secondari
hyperimmun
respons
may
advantag
function
properti
improv
finespecif
immunolog
unchalleng
exploit
particular
antibodi
pool
therapeut
purpos
aim
gener
librari
collect
independ
combin
igg
repertoir
b
cell
previous
encount
defin
target
antigen
cours
diseas
present
studi
employ
lymphnod
deriv
b
cell
repertoir
clone
individu
phage
display
librari
scfv
antibodi
format
seven
librari
deriv
donor
high
serum
titer
herp
simplex
viru
hsv
employ
pan
viral
glycoprotein
b
gb
serv
entri
receptor
viral
data
show
high
affin
scfv
hsvneutral
properti
could
success
select
approach
lyndal
concept
base
clone
individu
lymph
node
igg
donor
repertoir
total
donor
lymph
node
includ
gener
individu
sublibrari
vhvlkappa
vhvllambda
repertoir
respect
size
individu
lyndal
list
tabl
averag
sublibrari
consist
independ
member
thu
donor
repertoir
total
size
final
lyndal
librari
collect
compris
sublibrari
approxim
clone
select
specif
binder
phage
display
librari
requir
express
correctli
fold
scfv
fragment
phage
surfac
qualiti
lyndal
repertoir
therefor
character
gene
protein
level
sequenc
clone
donor
contain
fulllength
scfv
insert
similar
proport
kappa
lambda
sublibrari
respect
tabl
evalu
number
solubl
express
scfv
e
coli
analyz
induc
periplasm
prepar
randomli
pick
clone
lyndal
collect
dot
blot
western
blot
analysi
eightytwo
percent
lyndal
clone
investig
dot
blot
screen
express
solubl
antibodypiii
fusion
protein
fig
compar
express
rate
kappa
lambda
light
chain
sublibrari
respect
tabl
proport
detect
antibodypiii
fusion
correl
well
complet
insert
analyz
coloni
pcr
r
similar
result
obtain
antipiii
western
blot
express
intact
scfvpiii
fusion
protein
shown
clone
chosen
random
posit
dot
blot
signal
fig
thu
total
lyndal
clone
could
express
complet
scfvpiii
fusion
protein
basi
analys
current
lyndal
collect
estim
consist
independ
clone
primer
set
use
lyndal
clone
design
pcr
amplif
known
function
human
antibodi
allel
famili
repres
antibodi
gene
databas
vbase
sequenc
analysi
randomli
pick
clone
vhvlkappa
vhvllambda
verifi
scfv
insert
perform
analyz
distribut
usag
germlin
gene
gene
famili
actual
amplifi
primer
set
identifi
vbase
annot
function
antibodi
gene
fig
known
human
v
gene
famili
fig
vh
vlkappa
vllambda
function
sequenc
identifi
fig
distribut
pattern
function
sequenc
lyndal
compar
three
larg
antibodi
gene
databas
vbase
imgt
consid
close
repres
natur
occur
distribut
fig
appar
differ
found
famili
occur
frequent
either
lyndal
ie
databas
entri
ie
next
step
assess
whether
pool
affinitymatur
antibodi
within
lyndal
collect
directli
access
antibodi
select
chose
envelop
glycoprotein
b
hsv
type
target
antibodi
select
high
preval
adult
world
popul
exclus
use
hsvexperienc
b
cell
repertoir
screen
lyndal
donor
librari
patient
confirm
serum
antibodi
respons
elisa
includ
test
serum
sampl
lyndal
donor
gbreactiv
od
signal
least
five
time
greater
nonimmun
control
od
sd
seven
librari
donor
high
igg
antibodi
titer
contain
total
clone
combin
select
specif
binder
success
enrich
fig
elisa
screen
monoclon
phage
round
reveal
increas
targetspecif
scfv
phage
antibodi
fig
fig
respect
subsequ
fingerprint
analys
clone
verifi
scfv
gene
fig
result
identif
individu
binder
screen
coloni
ie
everi
screen
coloni
encod
gbspecif
antibodi
uniqu
gene
sequenc
sequenc
analysi
reveal
variabl
gene
select
scfv
deriv
variou
germlin
sequenc
antibodi
famili
predomin
use
gene
famili
lambda
light
chain
fig
analyz
respect
vhvl
pair
scfv
partial
clonal
relat
analyz
antigendriven
affin
matur
enrich
scfv
number
somat
hypermut
determin
nucleotid
fig
amino
acid
level
fig
averag
vh
domain
possess
amino
acid
exchang
mutat
vl
domain
vs
consid
number
nucleotid
mutat
vh
vl
frequenc
nonsil
mutat
compar
variabl
gene
vh
vl
exclud
region
analysi
exchang
mutat
predominantli
accumul
within
cdr
highest
mutat
frequenc
follow
fig
analys
scfv
solubl
express
periplasm
e
coli
cell
purifi
immobil
metal
ion
affin
chromatographi
imac
fig
subject
size
exclus
chromatographi
sec
vast
major
investig
antibodi
fragment
elut
predominantli
scfv
monom
fig
flow
cytometri
use
vero
cell
either
infect
scfv
bound
specif
membraneassoci
gb
member
herp
viru
famili
bind
found
uninfect
vero
cell
fig
flow
cytometr
competit
assay
four
randomli
select
scfv
presenc
molar
excess
recombin
confirm
antigen
specif
lyndal
scfv
fig
obtain
immunofluoresc
signal
tend
stronger
infect
cell
probabl
due
known
higher
genom
copi
number
compar
notabl
scfv
show
almost
three
time
greater
reactiv
toward
infect
cell
could
indic
bind
nonshar
epitop
gb
fig
accur
measur
equilibrium
constant
kd
scfv
bind
target
antigen
natur
context
first
perform
flow
cytometr
affin
measur
randomli
chosen
scfv
monom
infect
cell
tabl
scfv
bound
target
antigen
kd
valu
nanomolar
rang
subsequ
surfac
plasmon
reson
spr
affin
measur
clone
confirm
tight
bind
r
select
scfv
tabl
fig
evalu
scfv
mediat
therapeut
relev
antivir
activ
next
test
abil
prevent
hsv
infect
vitro
use
standard
plaqu
neutral
assay
eight
scfv
hsvneutral
activ
clone
exhibit
highest
antivir
potenc
therefor
analyz
previous
shown
valenc
gbspecif
antibodi
may
strong
effect
hsvneutral
clone
elut
gel
filtrat
chromatographi
calibr
superdex
column
two
peak
retent
time
correl
size
monom
kda
noncoval
associ
dimer
scfv
fragment
kda
antibodi
fraction
therefor
separ
prepar
size
exclus
chromatographi
fig
independ
character
bival
bind
dimer
scfv
result
increas
avid
glycoprotein
b
surfac
hsv
infect
cell
appar
equilibrium
constant
nm
nm
monomer
scfv
show
weak
bind
kd
nm
nm
respect
fig
similar
affin
scfv
scfv
bind
infect
cell
indic
antibodi
must
recogn
epitop
share
strain
evalu
neutral
activ
show
dimer
scfv
inde
neutral
hsv
serotyp
significantli
better
monomer
scfv
fig
surprisingli
monomer
scfv
dimer
scfv
neutral
higher
efficaci
efficaci
dimer
scfv
neutral
even
favor
human
mab
current
develop
clinic
applic
acyclovirresist
humor
immun
respons
play
critic
role
acquir
immun
infecti
diseas
demonstr
singl
b
cell
express
clone
singl
antibodi
develop
natur
cours
infect
patient
may
exhibit
strong
capac
broadli
neutral
viral
pathogen
influenza
despit
still
limit
understand
antibodi
contribut
actual
control
especi
chronic
infecti
diseas
live
organ
seem
clear
undergo
affin
matur
lymphoid
retriev
particular
v
gene
repertoir
sourc
librari
construct
highli
attract
repertoir
may
enabl
discoveri
develop
antibodi
potenti
uniqu
function
properti
access
human
immun
repertoir
gener
restrict
peripher
blood
bone
marrow
describ
altern
approach
recov
function
mab
combinatori
antibodi
phage
display
librari
deriv
lymph
node
sourc
immun
repertoir
underli
idea
lyndal
concept
base
assumpt
human
immun
librari
clone
antigenencount
antibodi
repertoir
may
uniqu
antigenspecif
biolog
properti
exploit
therapeut
intervent
lymph
node
appear
highli
valuabl
sourc
immun
librari
fundament
process
humor
immun
take
place
within
germin
center
somat
hypermut
class
switch
recombin
differenti
clonal
expand
bcell
memori
b
plasma
moreov
lymph
node
contain
high
number
antigenencount
activ
b
includ
conceptu
interest
subset
reenter
reactiv
igg
posit
memori
cell
harbor
extens
somat
sinc
select
hivneutr
mab
antigenspecif
memori
b
cell
memori
b
cell
popul
gener
might
repres
crucial
antibodi
gene
pool
select
antivir
antibodi
uniqu
biolog
properti
base
consider
employ
lymph
nodederiv
memori
b
cell
popul
donor
clone
independ
combin
igg
repertoir
combin
size
independ
antibodi
clone
lyndal
repres
knowledg
one
largest
lymph
nodederiv
antibodi
librari
date
demonstr
proofofconcept
extract
high
affin
antivir
antibodi
combinatori
repertori
immun
donor
combin
sublibrari
individu
high
targetspecif
igg
titer
pan
hsv
chosen
target
antibodi
select
high
infect
preval
popul
previous
report
success
antibodi
select
hsvseroposit
bone
marrow
shown
screen
lyndal
donor
humor
respons
hsv
result
high
rate
uniqu
high
affin
binder
broad
represent
differ
germlin
sequenc
variou
antibodi
famili
notabl
variabl
region
isol
scfv
accumul
particularli
high
degre
somat
hypermut
result
averag
number
mutat
amino
acid
higher
report
hyperimmun
vaccin
individu
vs
hypothes
repres
fulli
matur
humor
immun
thu
lyndal
concept
allow
select
hsvspecif
antibodi
matur
cours
natur
occur
immun
respons
assess
whether
high
degre
somat
hypermut
would
also
translat
favor
function
properti
select
antibodi
perform
hsv
neutral
assay
despit
quit
limit
number
analyz
clone
sever
scfv
exhibit
potent
antivir
activ
notabl
neutral
properti
one
clone
remark
explor
antivir
efficaci
hsv
infect
mice
warrant
conclud
antigenencount
lymph
node
b
cell
repertoir
sever
donor
may
provid
valuabl
altern
select
high
affin
antibodi
immunolog
uniqu
function
properti
remain
shown
futur
may
also
translat
antibodi
superior
therapeut
activ
compar
antibodi
obtain
larg
synthet
semisynthet
librari
show
valu
lymph
node
derivedimmun
librari
isol
vivo
matur
mab
promis
virusneutr
properti
expect
lyndal
concept
also
extend
diseasespecif
target
studi
approv
ethic
committe
faculti
medicin
heidelberg
univers
patient
provid
written
inform
consent
lymph
node
obtain
donor
undergo
surgeri
dissect
lymph
node
transfer
directli
rnalat
reagent
qiagen
store
individu
lymph
node
thaw
room
temperatur
rt
homogen
use
tissueruptor
qiagen
total
rna
isol
use
rneasi
lipid
tissu
midi
kit
qiagen
singl
strand
cdna
prepar
use
first
strand
cdna
synthesi
kit
thermo
fisher
scientif
librari
gener
randomli
combin
amplifi
human
vh
vl
gene
phagemid
vector
pheni
deriv
contain
hexahistidin
cmyctag
encod
sequenc
variabl
domain
gene
clone
scfv
fragment
vhvl
orient
link
amino
acid
encod
peptid
igg
v
region
repertoir
human
donor
amplifi
twostep
seminest
pcr
strategi
use
primer
maximum
two
degener
nucleotid
posit
forward
primer
design
base
function
variabl
gene
sequenc
repres
vbase
http
revers
primer
bound
constant
gene
kappa
lambda
j
encod
segment
design
basi
sequenc
inform
vbase
databas
respect
vh
vlkappa
vllambda
encod
gene
repertoir
separ
amplifi
prepar
cdna
sever
independ
pcr
use
unitsreact
pfu
polymeras
thermo
fisher
scientif
antibodi
gene
pcramplifi
first
set
pcr
pcr
cycl
follow
reamplif
pcr
product
pcr
cycl
introduc
clone
restrict
site
use
pcr
program
min
initi
denatur
follow
cycl
min
min
min
final
elong
amplifi
vh
gene
repertoir
subclon
sfiixhoifrag
follow
electropor
phagemid
electrocompet
e
coli
cell
agil
technolog
light
chain
kappa
lambda
repertoir
separ
clone
apalinotifrag
vhcontain
phagemid
librarycontain
phagemid
vector
transform
electropor
n
per
donor
e
coli
thu
creat
two
independ
librari
vhvlkappa
vhvllambda
transform
bacteria
spread
mm
agar
plate
contain
wv
glucos
ampicillin
overnight
growth
individu
donor
librari
store
glycerol
final
stock
aliquot
determin
lyndal
size
two
transform
sampl
per
sublibrari
randomli
chosen
incub
h
serial
dilut
cell
plate
agar
plate
next
day
respect
librari
size
calcul
extrapol
averag
bacteri
number
dilut
countabl
coloni
randomli
pick
transform
per
sublibrari
analyz
coloni
pcr
success
integr
heavi
light
chain
gene
fragment
size
sequenc
least
five
intact
randomli
chosen
scfv
per
sublibrari
determin
analyz
sequenc
align
softwar
dnaplot
http
identifi
closest
germlin
v
j
segment
gene
deposit
vbase
complementaritydetermin
region
cdr
addit
analyz
use
fab
analysi
tool
http
align
scfv
sequenc
rel
gene
famili
occurr
sequenc
lyndal
clone
calcul
compar
mean
distribut
function
v
gene
entri
human
antibodi
databas
vbase
clone
nonfunct
read
frame
orphan
pseudogen
exclud
analysi
sublibrari
analyz
solubl
express
antibodypiii
fusion
e
coli
dot
blot
western
blot
analysi
individu
coloni
inocul
plate
medium
grown
shaker
induct
plate
contain
glucos
inocul
cultur
incub
addit
h
solubl
express
antibodypiii
fusion
induc
ad
mm
isopropyl
iptg
express
pellet
bacteria
xg
min
resuspend
periplasm
prepar
buffer
mm
trishcl
ph
mm
edta
sucros
contain
freshli
prepar
lysozym
incub
min
ice
ad
final
concentr
mm
clarifi
periplasm
fraction
xg
min
either
appli
onto
nitrocellulos
membran
use
minifold
dot
blot
system
whatman
dot
blot
analysi
onto
sdspage
reduc
condit
western
blot
analysi
antibodypiii
fusion
detect
use
either
peroxidaseconjug
anticmyc
antibodi
roch
diagnost
mous
antipiii
antibodi
mobitec
first
goat
antimous
igg
peroxidas
conjug
jackson
immunoresearch
laboratori
secondari
antibodi
peroxidas
activ
detect
chemiluminesc
use
ecl
substrat
thermo
fisher
scientif
chemic
film
curix
plu
agfa
healthcar
select
herp
simplex
viru
specif
scfv
use
antigenco
immunotub
perform
describ
follow
modif
antibodi
repertoir
seven
lyndal
donor
separ
packag
inocul
ytga
medium
mldonor
correspond
librari
glycerol
stock
follow
superinfect
helper
phage
agil
technolog
multipl
infect
express
antibodypiii
fusion
induc
resuspend
pellet
bacteria
induct
medium
yt
ampicillin
kanamycin
mm
iptg
incub
combin
librari
shaker
h
phage
purifi
two
pegprecipit
step
incub
h
ice
respect
preincub
tu
transduc
unit
mpb
h
rt
phage
appli
without
deplet
step
gb
pb
block
immunotub
bind
phage
target
protein
occur
rollov
shake
min
min
rest
rt
wash
pbst
pb
bound
phage
antibodi
elut
acid
solut
glycinehcl
nacl
ph
incub
min
rt
rotat
elut
phage
antibodi
neutral
ph
trishcl
ph
ad
logphas
rescu
nonelut
phage
select
tube
addit
fill
logphas
bacteria
infect
cultur
combin
continu
two
select
round
perform
prepar
ml
start
cultur
increas
stringenc
pan
employ
less
antigen
coat
wash
cycl
round
round
pb
pbst
respect
polyclon
phage
elisa
ppelisa
perform
describ
ad
tuwel
rescu
phage
antigenco
microtit
plate
monoclon
phage
elisa
mpelisa
singl
coloni
posit
enrich
pan
round
inocul
microtit
plate
contain
ytga
cultur
shaken
use
inocul
infect
plate
fresh
medium
master
clone
store
ad
glycerol
incub
infect
plate
h
bacteria
superinfect
tuwel
helper
phage
follow
resuspens
pellet
induct
medium
antibodypiii
express
shake
next
day
clone
analyz
bind
coat
select
antigen
pb
control
antigen
mpb
respect
incub
block
well
mpb
h
rt
phage
supernat
mpb
h
rt
detect
use
hrpconjug
antibodi
ge
healthcar
perform
absorb
read
nm
use
genio
plu
reader
tecan
read
ten
time
higher
averag
signal
milk
protein
consid
antigenspecif
bind
integr
scfv
gene
specif
binder
assess
coloni
pcr
reamplifi
gene
digest
bstni
fingerprint
analysi
sequenc
germlin
sequenc
respect
antibodi
gene
famili
determin
dnaplot
follow
construct
phylogenet
tree
phylogenyfr
web
somat
hypermut
analysi
select
scfv
perform
employ
imgtvquest
onlin
scfv
encod
gene
pcramplifi
subclon
sfiinoti
fragment
express
vector
solubl
protein
express
bacteri
periplasm
describ
hexahistidinetag
scfv
purifi
imac
nisepharos
fast
flow
ge
healthcar
accord
manufactur
recommend
oligomer
state
imacpurifi
scfv
analyz
buffer
exchang
pb
sec
superdex
gl
column
use
fplc
system
ge
healthcar
column
calibr
use
gel
filtrat
low
molecular
weight
standard
amersham
bioscienc
elut
profil
record
monitor
absorb
nm
elut
volum
determin
unicorn
softwar
necessari
scfv
purifi
homogen
prepar
sec
hiload
superdex
column
ge
healthcar
purifi
scfv
concentr
centrifug
filter
unit
filter
steril
concentr
measur
spectrophotometr
specif
bind
purifi
scfv
nativ
gb
protein
evalu
flow
cytometri
use
african
green
monkey
kidney
cell
line
vero
ecacc
either
infect
noninfect
f
g
infect
fluoresc
measur
perform
describ
detect
bound
scfv
nm
mous
anticmyc
igg
goat
antimous
fluorescein
isothiocyan
fitc
conjug
jackson
immunoresearch
laboratori
fluoresc
measur
facscanto
ii
flow
cytomet
mean
fluoresc
intens
calcul
use
fac
diva
softwar
becton
dickinson
determin
equilibriumbind
curv
infect
vero
cell
incub
triplic
scfv
dilut
nm
follow
detect
describ
background
fluoresc
subtract
measur
median
fluoresc
intens
rel
affin
calcul
nonlinear
regress
use
graphpad
prism
version
graphpad
softwar
bind
kinet
determin
spr
biacor
system
ge
healthcar
standard
coupl
protocol
employ
immobil
gb
via
expos
primari
amin
sensor
chip
ge
healthcar
surfac
activ
flow
cell
min
perform
mixtur
nh
nhydroxysuccinimid
edc
carbodiimid
hydrochlorid
flow
rate
immobil
ligand
mm
sodium
acet
ph
min
flow
rate
densiti
ru
flow
cell
residu
reactiv
site
block
inject
ethanolamin
ph
min
flow
cell
serv
refer
surfac
measur
kinet
increas
concentr
nm
nm
nm
nm
nm
nm
nm
purifi
monomer
scfv
inject
run
buffer
mm
hepe
mm
nacl
ph
flow
rate
analyteligand
associ
dissoci
phase
monitor
min
min
respect
surfac
regener
run
buffer
min
data
global
fit
langmuir
bind
model
use
biaevalu
softwar
neutral
activ
lyndal
antibodi
determin
plaqu
reduct
assay
describ
human
version
highli
potent
hsvneutral
antibodi
use
posit
